India has witnessed a significant stride in the healthcare sector with the launch of Mounjaro, a groundbreaking anti-diabetes and obesity drug, by the US-based pharmaceutical giant Eli Lilly. The drug, containing the active ingredient tirzepatide, received marketing authorization from India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO). Mounjaro is now available in India in a single-dose vial, promising to revolutionize the management of type 2 diabetes and obesity in the country.

The Need for Mounjaro in India

India is grappling with a dual epidemic of diabetes and obesity, making these two health challenges a significant burden on the nation’s healthcare system. According to recent statistics, India is home to approximately 101 million people living with diabetes, nearly half of whom struggle to manage their blood sugar levels effectively. Obesity, a critical risk factor for diabetes, affects about 100 million Indians, contributing to high blood pressure, heart disease, sleep disorders, and other health complications.

Related News

Recognizing the urgency of this health crisis, Eli Lilly India aims to collaborate with the Indian government and healthcare industry to enhance awareness and improve treatment options. Winselow Tucker, President of Lilly India, emphasized the company’s commitment, stating, “Our goal is to help people with obesity and diabetes live healthier lives. The launch of Mounjaro is part of our commitment to bringing innovative medicines to India.”

What is Mounjaro?

Mounjaro is a once-a-week prescription drug designed to manage type 2 diabetes and support weight management. The drug works by activating two critical hormones: Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1). These hormones play a vital role in controlling blood sugar levels and appetite, making Mounjaro an effective tool in managing both diabetes and obesity.

The drug is recommended for:

  • Adults with obesity (BMI of 30 or more)
  • Adults who are overweight (BMI of 27 or more) and have other weight-related health issues
  • Adults with type 2 diabetes to help manage blood sugar levels

Mounjaro is intended to be used alongside a healthy diet and regular exercise to maximize its benefits.

Clinical Trials and Efficacy

Mounjaro’s approval is backed by robust clinical trials showcasing its effectiveness in weight loss and blood sugar control. Two major global studies, SURMOUNT-1 and SURPASS, provided compelling evidence of the drug’s efficacy.

SURMOUNT-1: Weight Loss Study

This study involved 2,539 adults with obesity or excess weight who received Mounjaro along with a controlled diet and exercise regimen over 72 weeks. The results were striking:

  • Highest Dose (15 mg): Average weight loss of 21.8 kg
  • Lowest Dose (5 mg): Average weight loss of 15.4 kg
  • Placebo Group: Only 3.2 kg average weight loss

These results highlight Mounjaro’s significant potential in helping individuals achieve substantial weight loss compared to placebo.

SURPASS: Diabetes Control Study

The SURPASS study evaluated Mounjaro’s ability to control blood sugar levels when used alongside other diabetes medications over 40 weeks. Participants experienced a reduction in HbA1c (A1C) levels by up to 2.4%, marking a considerable improvement in blood sugar management.

These studies reinforce Mounjaro’s dual benefits in both weight reduction and diabetes control, positioning it as a vital addition to India’s healthcare arsenal.

How Mounjaro Works

Mounjaro operates through multiple mechanisms to enhance the body’s ability to manage diabetes and obesity effectively:

  1. Enhanced Insulin Release: Mounjaro stimulates the pancreas to release insulin more efficiently when blood sugar levels are high, helping maintain better glycemic control.

  2. Reduction of Glucagon Levels: Glucagon is a hormone that increases blood sugar levels by signaling the liver to release stored glucose. Mounjaro lowers glucagon levels, preventing unnecessary sugar release into the bloodstream.

  3. Improved Insulin Sensitivity: The drug increases the body’s responsiveness to insulin, aiding better glucose uptake by the muscles and tissues.

  4. Slowed Digestion: Mounjaro slows down the digestion process, allowing for more stable blood sugar levels and prolonging the feeling of fullness, which aids in weight management.

  5. Reduced Food Intake and Fat Storage: The appetite-suppressing effect helps reduce food intake and prevents fat accumulation, essential for weight loss and diabetes management.

Government Collaboration and Future Prospects

In July 2024, India’s drug regulator CDSCO approved tirzepatide, the active ingredient in Mounjaro, following a positive recommendation from a subject expert committee. Eli Lilly India is keen on working closely with the Indian government to improve diabetes and obesity management across the country.

Union Health Minister J.P. Nadda, in his statement, highlighted the progress India has made in healthcare with the support of the Gates Foundation, particularly in maternal health, immunization, and sanitation. Similarly, the government’s collaboration with pharmaceutical companies like Eli Lilly aims to enhance treatment accessibility and affordability for diabetes and obesity patients.

Addressing Diabetes and Obesity in India

India’s battle against diabetes and obesity requires a multifaceted approach involving lifestyle changes, awareness campaigns, and effective medical interventions. The government’s emphasis on preventive healthcare and chronic disease management aligns well with Mounjaro’s introduction to the market.

Dr. Manish Mistry, Senior Medical Director at Eli Lilly India, underlined the need for effective long-term solutions, stating, “Obesity and diabetes can cause serious health problems, so we need strong, long-term solutions. Mounjaro offers a new way to manage these conditions.”

Healthcare experts recommend a holistic approach to managing diabetes and obesity:

  • Regular Physical Activity: Engaging in at least 150 minutes of moderate exercise per week.
  • Balanced Diet: Including fiber-rich foods, lean proteins, and healthy fats while avoiding processed and sugary foods.
  • Regular Monitoring: Frequent blood sugar level checks for diabetics to ensure optimal control.
  • Weight Management: Achieving and maintaining a healthy weight to reduce diabetes risk.

The Role of Artificial Intelligence in Healthcare

During his visit to India, Bill Gates also emphasized the potential of Artificial Intelligence (AI) and predictive analytics in improving healthcare service delivery. AI can enhance diagnostic accuracy, personalize treatment plans, and optimize resource allocation in healthcare settings.

Andhra Pradesh Chief Minister N. Chandrababu Naidu expressed his enthusiasm for integrating AI into healthcare, education, agriculture, and employment sectors, aligning with the vision of ‘Swarna Andhra Pradesh 2047’. Naidu stated, “We believe this partnership with the Gates Foundation will play a crucial role in empowering our people and achieving this goal.”

AI integration in healthcare could involve:

  • Predictive Analytics: Forecasting disease outbreaks and managing healthcare resources effectively.
  • Telemedicine: Enhancing access to healthcare services in remote areas.
  • Personalized Medicine: Tailoring treatment plans based on individual genetic profiles and health conditions.

The launch of Mounjaro in India marks a significant milestone in the country’s fight against diabetes and obesity. With its dual-action mechanism and impressive clinical trial results, Mounjaro offers hope for millions struggling with these conditions. As India continues to battle the diabetes and obesity epidemic, innovative drugs like Mounjaro, coupled with government initiatives and AI integration, can pave the way for a healthier and more resilient nation.

Eli Lilly’s commitment to enhancing healthcare accessibility and affordability in India will undoubtedly play a crucial role in improving the quality of life for individuals with diabetes and obesity. The healthcare landscape in India is set for a transformative change with Mounjaro’s entry, offering new possibilities in chronic disease management.